Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, MD, Alessandra Iurlo, MD, Gabriele Gugliotta, MD PhD, Alessia Tieghi, MD, Lucia Canafoglia, MD, Raffaele Palmieri, MD, Crescenza Pasciolla, MD, Nicola Vianelli, MD, Riccardo Ragionieri, Erminia Rinaldi, MD, Emilio Usala, MD, Giorgio La Nasa, MD, Alessandra Perra, MD, Giuseppe Tagariello, MD, Nilla Maschio, MD, Emma Cacciola, PhD, Rossella Rosaria Cacciola, PhD, Micaela Bergamaschi, MD, Anna Da Col, MD, Angela Rago, MD, Lorenzo Rizzo, MD, Francesco Spina, MD, Daniele Cattaneo, MD, Daniela Lambertenghi, MD, Aniello Casoria, MD, Maria Langella, Maria Luigia Randi, MD, Elisabetta Cosi, MD, Monica Crugnola, MD, Elena Masselli, MD, Paola Ranalli, MD, Giovanni Garozzo, MD, Katia Codeluppi, Oreste Villani, MD, Grazia Ferrara, Cristina Santoro, MD, Potito Rosario Scalzulli, MD, Manlio Ricciotti, MD, Viviana Appolloni, MD, Anna Candoni, MD, Annalisa Luraschi, MD, Rupoli Serena, MD, Mauro DI Ianni, MD, Giovanni Caocci, MD, Francesco Lanza, MD, Nicola Orofino, MD, Elisa Rumi, MD, Alfredo Dragani, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Umberto Santoro, Alessandro M. Vannucchi, MD PhD

Blood (2016) 128 (22): 5472.

https://doi.org/10.1182/blood.V128.22.5472.5472

Published: 2016

Journal Articles

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Blood (2016) 128 (22): 4494.

https://doi.org/10.1182/blood.V128.22.4494.4494

Published: 2016

Journal Articles

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

Luciana De Luca, Giovanni D'Arena, MD, Vittorio Simeon, PhD, Stefania Trino, PhD, Ilaria Laurenzana, PhD, Antonella Caivano, Francesco La Rocca, Oreste Villani, MD, Giovanna Mansueto, MD, Silvia Deaglio, MD PhD, Idanna Innocenti, MD, Luca Laurenti, Stefano Molica, MD, Giuseppe Pietrantuono, MD, Angelo De Stradis, Luigi Del Vecchio, MD, Pellegrino Musto, MD

Blood (2016) 128 (22): 4375.

https://doi.org/10.1182/blood.V128.22.4375.4375

Published: 2016

Journal Articles

The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy

Blood (2014) 124 (21): 4740.

https://doi.org/10.1182/blood.V124.21.4740.4740

Published: 2014

Journal Articles

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

Blood (2013) 122 (21): 3211.

https://doi.org/10.1182/blood.V122.21.3211.3211

Published: 2013

Journal Articles

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

Blood (2013) 122 (21): 685.

https://doi.org/10.1182/blood.V122.21.685.685

Published: 2013

Journal Articles

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

Giovanni D'Arena, Roberto Guariglia, Giovanna Mansueto, Maria Carmen Martorelli, Giuseppe Pietrantuono, Oreste Villani, Rosa Lerose, Pellegrino Musto

Blood (2013) 121 (7): 1240–1242.

https://doi.org/10.1182/blood-2012-11-465575

Published: 2013

Journal Articles

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Antonella Caivano, Francesco La Rocca, Alessandra Favole, PhD, Sonia Carturan, PhD, Enrico Bracco, PhD, Oreste Villani, Giuseppe Pietrantuono, Ilaria Laurenzana, Luciana De Luca, MD, Annalisa Morano, Vittorio Simeon, Stefania Trino, Simona Berardi, Antonio Basile, Angelo Vacca, Pellegrino Musto, Daniela Cilloni, MD

Blood (2012) 120 (21): 2926.

https://doi.org/10.1182/blood.V120.21.2926.2926

Published: 2012

Journal Articles

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Blood (2012) 120 (21): 2971.

https://doi.org/10.1182/blood.V120.21.2971.2971

Published: 2012

Journal Articles

Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia

Blood (2012) 120 (21): 729.

https://doi.org/10.1182/blood.V120.21.729.729

Published: 2012

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients

Antonio Palumbo, MD, Sara Bringhen, Oreste Villani, Agostina Siniscalchi, MD, Eleonora Russo, MD, PhD, Giuseppina Uccello, MD, Chiara Cerrato, MD, Milena Gilestro, Davide Rossi, MD, Mario Boccadoro, MD

Blood (2012) 120 (21): 730.

https://doi.org/10.1182/blood.V120.21.730.730

Published: 2012

Journal Articles

Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

Blood (2011) 118 (21): 2925.

https://doi.org/10.1182/blood.V118.21.2925.2925

Published: 2011

Journal Articles

Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.

Esther Natalie Oliva, MD, Valeria Santini, MD, Poloni Antonella, MD, Vincenzo Liso, MD, Daniela Cilloni, MD, Adelmo Terenzi, MD, Patrizia Guglielmo, MD, Riccardo Ghio, MD, Agostino Cortelezzi, MD, Giampietro Semenzato, MD, Cristina Clissa, MD, Flavia Salvi, MD, Oreste Villani, MD, Maria Antonietta Aloe Spiriti, MD

Blood (2009) 114 (22): 3822.

https://doi.org/10.1182/blood.V114.22.3822.3822

Published: 2009

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome

Esther Natali e Oliva, MD, Cristina Clissa, MD, Valeria Santini, Antonella Poloni, MD, Vincenzo Liso, MD, Daniela Cilloni, MD, PhD, Adelmo Terenzi, MD, Stefana Impera, MD, Alessandro Levis, MD, Agostino Cortelezzi, MD, Riccardo Ghio, MD, Giampietro Semenzato, MD, Oreste Villani, MD, Maria Antonietta Aloe Spiriti, MD

Blood (2008) 112 (11): 2363.

https://doi.org/10.1182/blood.V112.11.2363.2363

Published: 2008

Journal Articles

5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial

Maria Teresa Voso, Valeria Santini, Carlo Finelli, Lorenza Borin, Emanuele Angelucci, Giuseppe Fioritoni, Benedetta Neri, Agostino Cortellezi, Oreste Villani, Francesco Buccisano, Giovanni Martinelli, Maria Concetta Petti, Gina Zini, Alfonso Piciocchi, Paola Fazi, Giuliana Alimena, Marco Gobbi, Vincenzo Liso, Giuseppe Leone

Blood (2008) 112 (11): 3648.

https://doi.org/10.1182/blood.V112.11.3648.3648

Published: 2008

Journal Articles

Efficacy of Lenalidomide in Primary Plasma Cell Leukemia.

Giuseppe Pietrantuono, Roberto Guariglia, Maria Carmen Martorelli, Oreste Villani, Fiorella D’Auria, Pellegrino Musto

Blood (2007) 110 (11): 4835.

https://doi.org/10.1182/blood.V110.11.4835.4835

Published: 2007

Journal Articles

Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.

Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Enrico Balleari, Alessandro Andriani, Giovanni D’Arena, Velia Bongarzoni, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Maria Carmen Martorelli, Fiorella D’Auria, Pasquale Niscola, Antonietta Falcone, Grazia Sanpaolo, Antonio Palumbo

Blood (2007) 110 (11): 534.

https://doi.org/10.1182/blood.V110.11.534.534

Published: 2007

Journal Articles

Darbepoetin 500 mcg Q3W, Alone or in Combination with Peg-Filgrastim, in Low/Int1 IPSS Risk Myelodysplastic Syndromes Unresponsive to Recombinant Erythropoietin.

Oreste Villani, Roberto Guariglia, Giuseppe Pietrantuono, Maria Carmen Martorelli, Fiorella D’Auria, Carla Papa, Rosa Lerose, Laura Campioni, Francesco Lanza, Pellegrino Musto

Blood (2007) 110 (11): 4606.

https://doi.org/10.1182/blood.V110.11.4606.4606

Published: 2007

NARROW

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients

Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia

Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome

5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial

Efficacy of Lenalidomide in Primary Plasma Cell Leukemia.

Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.

Darbepoetin 500 mcg Q3W, Alone or in Combination with Peg-Filgrastim, in Low/Int1 IPSS Risk Myelodysplastic Syndromes Unresponsive to Recombinant Erythropoietin.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only